Press Release: YMAB INVESTOR NOTICE: Robbins Geller Rudman & Dowd Announces that Y-mAbs Therapeutics, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit – YMAB
SAN DIEGO, Jan. 22, 2023 (GLOBE NEWSWIRE) -- The law firm of Robbins Geller Rudman & Dowd LLP announces that purchasers of Y-mAbs Therapeutics, Inc. (NASDAQ: YMAB) common stock on the open market, or pursuant to Registration Statements filed with the U.S. Securities and Exchange Commission (“SEC”), between October 6, 2020 and October 28, 2022,…
Press Release: YMAB INVESTOR NOTICE: Robbins Geller Rudman & Dowd Announces that Y-mAbs Therapeutics, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit – YMAB - Newscast
Thu, 19 Jan 2023 15:01:00 GMT Smith announces an investigation on behalf of Y-mAbs Therapeutics, Inc. (“Y-mAbs” or the “Company”) (NASDAQ: YMAB) investors ... www.howardsmithlaw.com. This press release may be ...
Thu, 19 Jan 2023 14:48:00 GMT Smith announces an investigation on behalf of Y-mAbs Therapeutics, Inc. (“Y-mAbs” or the “Company”) (NASDAQ: YMAB) investors concerning ...
Thu, 19 Jan 2023 10:41:00 GMT You can also contact attorney J.C. Sanchezof Robbins Geller by calling 800/449-4900 or via e-mail at jsanchez@rgrdlaw.com. CASE ALLEGATIONS: Y-mAbs is a biopharmaceutical company focused on the ...
Thu, 19 Jan 2023 09:55:00 GMT You can also contact attorney J.C. Sanchez of Robbins Geller by calling 800/449-4900 or via e-mail at jsanchez@rgrdlaw.com. CASE ALLEGATIONS: Y-mAbs is a biopharmaceutical company focused on the ...
Thu, 19 Jan 2023 09:44:00 GMT Robbins Geller Rudman & Dowd LLP announces that purchasers of Y-mAbs Therapeutics, Inc. (NASDAQ: YMAB) common stock on the open market, or pursuant to Registration Statements filed with the U.S ...
